Small Stocks, Big Money™

Lytus Technologies Holdings (Nasdaq: LYT) has introduced Radio Room, India's first regional audio OTT platform, enhancing its footprint in the digital entertainment sector with cutting-edge technology poised to redefine audio streaming. Offering a diverse range of audio dramas in genres like classic literature, crime thrillers, and children's stories, Radio Room caters to the Indian diaspora globally. Targeting four million subscribers in its first year, Radio Room aims to expand across numerous Indian regional languages and international languages, setting the stage for Lytus to become a global leader in digital entertainment.

Mobilicom (Nasdaq: MOB) received a follow-on order from a major loitering munitions provider with $4 billion in annual revenue for its 10” Ground Control Station (GCS). This move highlights Mobilicom's robust solutions for drones, catering to a market projected to reach $26.6 billion by 2030. The GCS, integrated with Mobilicom's SkyHopper PRO Micro datalink, supports multiple drone operations and offers military-grade performance. CEO Oren Elkayam noted the $240,000 order underscores the growing demand for UAVs, fueled by increasing defense budgets globally.

Enlivex Therapeutics (Nasdaq: ENLV) announced positive interim results from a Phase I/II trial of Allocetra™ for end-stage knee osteoarthritis. Patients indicated for knee replacement received a single injection of Allocetra™. At three months, data showed a significant 64% reduction in pain, with 33% of patients experiencing complete pain relief. Impressively, 89% of patients avoided knee replacement surgery. No severe adverse events were reported, highlighting Allocetra’s favorable safety profile. These results suggest Allocetra™ as a promising alternative for patients seeking to delay or avoid knee replacement surgery. Recruitment for the study continues, aiming for a total of 18 participants.

Nutriband (Nasdaq: NTRB) provided an update on its Aversa Fentanyl development, highlighting progress towards commercial manufacturing and a pivotal Phase 1 human abuse potential study. Partnering with Kindeva Drug Delivery, Nutriband aims to integrate its AVERSA™ abuse-deterrent technology into FDA-approved fentanyl patches. The recent validation of cleaning methods for aversive agents is a key milestone. Following the completion of the commercial manufacturing process, Nutriband plans to file an IND with the FDA. With potential annual US sales estimated at $80-200 million, Aversa Fentanyl is poised to enhance the safety of transdermal fentanyl patches.